Prophylactic antibiotics trial aims to reduce early delivery in previable PPROM

Preterm Premature Rupture of Membranes (PPROM), occurring before 37 weeks of gestation, poses a significant threat, particularly when it happens at previable stages (less than 22 weeks). This condition is strongly associated with severe maternal morbidity and mortality, primarily due to ascending infections, sepsis, and chorioamnionitis. Current management often involves expectant care, but the risk of infection leading to early delivery and adverse neonatal outcomes remains high. Research has historically focused more on term PROM, leaving a critical gap in understanding and managing previable PPROM, where interventions like prophylactic antibiotics could potentially mitigate these severe risks by preventing or delaying infection-related complications.

This study is designed as a clinical trial to evaluate the efficacy of prophylactic antibiotics in the expectant management of previable PPROM. The primary objective is to determine if antibiotic administration significantly reduces the rate of delivery within 7 days for pregnancies less than 22 weeks of gestation. A secondary objective focuses on pregnancies between 20 and 22 weeks, assessing if prophylactic antibiotics can decrease composite neonatal morbidity. The trial aims to compare outcomes in patients receiving antibiotics versus a control group (likely standard expectant management without routine prophylactic antibiotics, though not explicitly stated). Specific details regarding the antibiotic regimen, dosage, route, frequency, duration, and total participant n are not provided in the abstract.